Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium
Restricted accessOtherFirst published online October, 2010
Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium
In a previous case report, published in this journal, we described a postoperative delirium in a patient during recovery from parathyroidectomy. We noted that the delirium resembled serotonin toxicity and that the patient had been taking paroxetine until 2 days before surgery. We offered several tentative explanations for this event, including an adverse interaction between paroxetine and other agent(s) used in the course of the anaesthesia. Recent developments in characterisation of serotonin toxicity have prompted us to re-examine the clinical details surrounding this life-threatening event. It is now known to be important that the patient was given methylene blue, pre-operatively, to enable visualisation of the parathyroid glands. Methylene blue has been found to be a potent inhibitor of monoamine oxidase (MAO), and several cases of serotonin toxicity have been reported recently following its administration. All these cases are consistent with the well-known risk of serotonin toxicity when drugs that augment serotonergic transmission are given in combination with an MAO inhibitor. Methylene blue is used in a variety of surgical settings as well as for treatment of various types of hypotensive shock and methemoglobinaemia. It is also being studied for treatment of Alzheimer’s disease and malaria. In this paper, we outline the pharmacology of methylene blue and the aetiology of serotonin toxicity to help prevent further unintentional co-administration of drugs that risk precipitating this life-threatening drug interaction.
Aeschlimann, C., Cerny, T., Kupfer, A. ( 1996) Inhibition of (mono) amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metabolism Disposition243: 1336- 1339.
2.
Akoachere, M., Buchholz, K., Fischer, E., Burhenne, J., Haefeli, WE, Schirmer, RH, et al. (2005) In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic actions with artemisinins. Antimicrob Agents Chemother49: 4592-4597.
3.
Bach, KK, Lindsay, FW, Berg, LS, Howard, RS ( 2004) Prolonged postoperative disorientation after methylene blue infusion during parathyoidectomy. Anesth Analg99: 1573-1574.
4.
de Baerdemaeker, L., Audenaert, K., Peremans, K. ( 2005) Anaesthesia for patients with mood disorders. Curr Opin Anaesthesiol18: 333-338.
5.
Calloway, NL, Riha, PD, Bruchey, AK, Munshi, Z., Gonzalez-Lima, F. ( 2004) Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol Biochem Behav77: 175-181.
6.
Deiana, S., Harrington, CR, Wischik, CM, Riedel, G (2009) Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacol202: 53-65.
7.
Denys, D., van Nieuwerburgh, F., Deforce, D., Westenberg, HG ( 2007) Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomised, double-blind trial. J Clin Psychiatry68: 747-753.
8.
Dunkley, EJ, Isbister, GK, Sibbritt, D., Dawson, AH, Whyte, IM ( 2003) The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Q J Med96: 635- 642.
9.
Eberhart, LH, Doderlein, F., Eisenhardt, G., Kranke, P., Sessler, DI, Torossian, A., et al. (2005) Independent risk factors for postoperative shivering. Anesth Analg101: 1849-1857.
10.
Faber, P., Ronald, A., Millar, BW ( 2005) Methylthioninium chloride: pharmacology and clinical applications with special emphasis on nitric oxide mediated vasoduiatory shock during cardiopulmonary bypass. Anaesthesia60: 575-587.
11.
George, M., Al-Duaij, N., ODonnell, KA, Shannon, MW ( 2008) Obtundation and seizure following ondansetron overdose in an infant. Clinical Toxicol46: 1064-1066.
12.
Gillman, PK ( 1999) The serotonin syndrome and its treatment. J Psychopharmacol13: 100-109.
13.
Gillman, PK ( 2006a) A review of serotonin toxicity data: Implications for the mechanisms of antidepressant drug action. Biol Psychiatry59: 1046-1051.
14.
Gillman, PK ( 2006b) Extracting value from case reports: lessons from serotonin toxicity (serotonin syndrome). Anaesthesia61: 419-422.
15.
Gillman, PK ( 2006c) Methylene blue implicated in potentially fatal serotonin toxicity. Anaesthesia61: 1013-1014.
16.
Hattori, M., Sugino, E., Minoura, K., In, Y., Sumida, M., Taniguchi, T., et al. (2008) Different inhibitory response of cyanidin and methylene blue for filament formation of tau microtubule-binding domain . Biochem Biophys Res Comm374: 158-163.
17.
Isbister, GK, Bowe, SJ, Dawson, A., Whyte, IM ( 2004) Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol42: 277-285.
18.
Isbister, GK, Buckley, NA, Whyte, IM ( 2007) Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust187: 361-365.
19.
Isbister, GK, Hackett, LP, Dawson, AH, Whyte, IM, Smith, AJ ( 2003) Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol56: 441-450.
20.
Kartha, SS, Chacko, CE, Bumpous, JM, Fleming, M., Lentsch, EJ, Flynn, MB ( 2006) Toxic metabolic encephalopathy after parathyroidectomy with methylene blue localization. Otolaryngol Head Neck Surg135: 765-768.
21.
Kaye, CM, Haddock, RE, Langley, PF, Mellows, G., Tasker, TC, Zussman, BD, et al. (1989) A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand350(Suppl.): 60-75.
22.
Khan, MAS, North, AP, Chadwick, DR ( 2007) Prolonged postoperative altered mental status after methylene blue infusion during parathryoidectomy: a case report and review of the literature . Ann R Coll Surg Engl89: 186-189.
23.
Kupfer, A., Aeschlimann, C., Cerny, T. ( 1996) Methylne blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharm50: 249-252.
24.
Levin, RL, Degrange, A., Bruno, GF, del Mazo, CD, Taborda, DJ, Griotti, JJ, et al. (2004) Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg77: 496-499.
25.
Mariak, Z., Lebkowski, W., Lyson, T., Lewko, J., Piekarski, P. ( 1999) Brain temperature during craniotomy in general anaesthesia . Neurol Neurochir Pol33: 1325-1337.
26.
Martindale, SJ, Stedeford, JC ( 2003) Neurological sequelae following methylene blue injection for parathyroidectomy. Anaesthesia58: 1041-1042.
27.
Mayer, B., Bunner, F., Schmidt, K. ( 1993) Inhibition of nitric oxide synthesis by methylene blue . Biochem Pharmacol45: 367-374.
28.
Mhra (2008) Methylthioninium chloride (methylene blue): CNS toxicity with serotonergic drugs. Drug Saf Update1: 5.
29.
Mihai, R., Mitchell, EW, Warwick, J. ( 2007) Dose-response and postoperative confusion following methylene blue infusion during parathyroidectomy. Can. J. Anaesth. 54: 79-81.
30.
Mitchell, RS ( 1955) Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Ann Intern Med42: 417-424.
31.
Murphy, GM, Hollander, SB, Rodrigues, HE, Kremer, C., Schatzberg, AF ( 2008) Effects of the serotonin transporter gene promotor polymorphism on mirtazepine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatr61: 1163-1169.
32.
Naylor, GJ, Smithe, AHW, Connelly, P. ( 1987) A controlled trial of methylene blue in severe depressive illness. Biol Psychiatry22: 657-659.
33.
Oates, JA, Sjoerdsma, A. ( 1960) Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology10: 1076-1078.
34.
Ochiai, Y., Itoh, K., Sakurai, E., Adachi, M., Tanaka, Y. ( 2006) Substrate selectivity of monoamine oxidase A, monoamine oxidase B, diamine oxidase, and semicarbazide-sensitive amine oxidase in COS-1 expression systems. Biol Pharm Bull29: 2362-2366.
35.
Oxenkrug, GF, Sablin, SO, Requintina, PJ ( 2007) Effect of methylene blue and related redox dyes on monoamine oxidase activity; rat pineal content of N-acetylserotonin, melatonin and related indoles; and righting reflex in melatonin-primed frogs. Ann NY Acad Sci1122: 245-252.
36.
Peter, C., Hongwan, D., Kupfer, A., Lauterburg, BH ( 2000) Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol56: 247-250.
37.
Ramsay, RR, Dunford, C., Gillman, PK ( 2007) Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol152: 946-951.
38.
Riedel, W., Lang, U., Oetjen, U., Schlapp, U., Shibata, M. ( 2003) Inhibition of oxygen radical formation by methylene blue, aspirin, or α-lipoic acid, prevents bacterial-lipopolysaccharide-induced fever. Mol Cell Biochem247: 83-94.
39.
Riha, PD, Bruchey, AK, Echevarria, DJ, Gonzalez-Lima, F. ( 2005) Memory facilitation by methylene blue: dose-dependent effect on behaviour and brain oxygen consumption. Eur J Pharmacol511: 151-158.
40.
Siebert, C., Kroeber, S., Lutter, N. ( 2005) Prolonged postoperative disorientation after methylene blue infusion during parathyroidectomy. Anesth Analg101: 606-615.
41.
Shanmugam, G., Kent, B., Kirby, S., Baskett, R. ( 2008) Serotonin syndrome following cardiac surgery. Interact Cardiovasc Thorac Surg7: 656-657.
42.
Stanford, BJ, Stanford, SC ( 1999) Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine?J Psychopharmacol13: 313-317.
43.
Stanford, SC, Stanford, BJ ( 2000) Reply to J.L Palmer - Postoperative delirium indicating an adverse drug reaction involving selective serotonin reuptake inhibitor, paroxetine?J Psychopharmacol (Oxf) 14: 186-187.
Tanaka, M., Kobayashi, D., Murakami, Y., Ozaki, N., Suzuki, T., Iwata, N., et al. (2008) Genetic polymorphisms in the 5-hydroxytrypamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol11: 261-267.
46.
Tyrer, P. ( 1979) Clinical use of monoamine oxidase inhibitors. In: Paykel, ES, Coppen, A (eds), Psychopharmacology of Affective Disorders . Oxford: Oxford Medical Publications , pp. 159-178.
47.
Ulus, IH, Maher, TJ, Wurtman, RJ ( 2000) Characterization of phentermins and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol59: 1611-1621.
48.
Volkee, V., Wegener, G., Vasar, E., Rosenberg, R. ( 1999) Methylene blue inhibits hippocampal nitric oxide synthase activity in vivo. Brain Res286: 303-305.
49.
Walter-Sack, I., Rengelshausen, J., Oberwittler, H., Burhenne, J., Mueller, O., Meissner, P., et al. (2009) High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol65: 179-189.
50.
Wischik, CM, Edwards, PC, Lai, RYKk, Roth, M., Harrington, CR ( 1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A93: 11213- 11218.
51.
Wrubel, KM, Riha, PD, Maldonado, MA, McCollum, D., Gonzalez-Lima, F. ( 2007) The brain metabolic enhancer methylene blue improves discrimination learning in rats. Pharmacol Biochem Behav86: 712-717.
